stockportfolio.pro
Ironwood Pharmaceuticals, Inc. (IRWD)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Ironwood Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $273.96M | $298.28M | $346.64M | $428.41M | $389.52M | $413.75M | $410.60M | $442.74M | $351.41M | $296.15M |
| Gross profit | $272.09M | $279.18M | $313.89M | $404.54M | $386.39M | — | $410.60M | — | — | — |
| Net income | $-81.71M | $-116.94M | $-282.37M | $21.50M | $106.18M | $528.45M | $175.06M | $-1.00B | $880,000 | $24.02M |
| Net margin | -29.8% | -39.2% | -81.5% | 5.0% | 27.3% | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% |
Source: Ironwood Pharmaceuticals, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into IRWD stock?
At today's market cap of $581.09M, Ironwood Pharmaceuticals, Inc. is priced for free-cash-flow growth of about -13.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $127.01M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -5.3%/yr over the last five fiscal years and revenue -5.3%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Ironwood Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IRWD in your portfolio →
Ironwood Pharmaceuticals, Inc. financial history by metric
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals, Inc. — frequently asked questions
What is Ironwood Pharmaceuticals, Inc.'s revenue?
Ironwood Pharmaceuticals, Inc. (IRWD) reported revenue of $296.15M for fiscal year 2025, down 15.7% from the prior year, according to its SEC filings.
Is Ironwood Pharmaceuticals, Inc. profitable?
Yes. IRWD earned net income of $24.02M in fiscal 2025, a net margin of 8.1%.
What is IRWD's P/E ratio?
Ironwood Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 5.7 based on the latest data in our nightly-refreshed cache.
How fast is Ironwood Pharmaceuticals, Inc. growing?
IRWD's revenue grew at roughly -5.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ironwood Pharmaceuticals, Inc. have?
As of fiscal year 2025, IRWD carried roughly $584.68M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ironwood Pharmaceuticals, Inc.'s market cap?
Ironwood Pharmaceuticals, Inc. (IRWD) has a market capitalization of about $581.09M, based on the latest data in our nightly-refreshed cache.
When does Ironwood Pharmaceuticals, Inc.'s fiscal year end?
IRWD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into IRWD stock?
At today's market cap of $581.09M, Ironwood Pharmaceuticals, Inc. is priced for free-cash-flow growth of about -13.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $127.01M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -5.3%/yr over the last five fiscal years and revenue -5.3%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Ironwood Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.